Cambrex, an East Rutherford-based small molecule company, announced on Thursday Tom Loewald has been named CEO and member of the board of directors, effective Sept. 7.
In the interim, the company will be led by an Office of the CEO comprised of Wayne Hewett, chairman of the board; Robert Green, executive vice president and chief financial officer; and Samantha Hanley, senior vice president and general counsel.
“Cambrex has a phenomenal reputation for providing unmatched expertise, innovation and customer service across the entire drug lifecycle, and I am thrilled to be joining the company at a time when bringing therapeutics to patients across the globe is more important than ever,” Loewald said. “I am eager to get to work, alongside the talented leadership team, to further solidify the company’s position as a leader in the CDMO market.”
Loewald currently serves as president of the flexibles division at ProAmpac, a packaging manufacturer. He is also on the board of directors at Harvard BioScience. Previously, he served in a variety of senior executive roles at Thermo Fisher Scientific, including chief commercial officer, president of the analytical instruments group, president of the laboratory products group and president of the laboratory equipment division. Earlier in his career, he held leadership roles at Tyco International and General Electric.
“Tom’s deep knowledge of life sciences and manufacturing, and strong commercial, operating and financial focus, make him the ideal leader for Cambrex as we approach this phase of accelerated growth. We are confident that he will be an excellent fit for the company’s customer-centric culture and look forward to supporting him and the entire team on the exciting road ahead,” Hewett said.
